XML 46 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended 12 Months Ended
Mar. 01, 2017
shares
Mar. 31, 2018
USD ($)
Distributor
Contract
shares
Mar. 31, 2017
USD ($)
Distributor
Dec. 31, 2017
USD ($)
Contract
shares
Sep. 30, 2016
shares
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Accumulated deficit   $ (2,883,410,000)   $ (2,854,898,000)  
Cash and cash equivalents   26,706,000   $ 43,946,000  
Principal amount of outstanding borrowings   $ 140,200,000      
Stock split of common stock 0.2        
Common stock, shares authorized | shares 140,000,000 280,000,000   280,000,000 700,000,000
Reverse stock split, description   The Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, prior to March 3, 2017, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.      
Net deferred revenue       $ 3,038,000  
Number of wholesale distributors | Distributor   3 3    
Percentage of product shipments to wholesale distributors   87.00% 93.00%    
Revenue - other     $ 1,750,000    
Third party logistics          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Net deferred revenue       $ 1,500,000  
AFREZZA product sales          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Percentage of estimated products returned   2.46%      
Bulk insulin sales          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Revenue - other     $ 1,700,000    
Insulin          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Loss on purchase commitments   $ 112,300,000      
Loss on purchase commitments, number of new contracts recognized | Contract   0   0  
Tranche B Notes          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Senior notes, effective interest rate   8.75%      
Principal amount of outstanding borrowings   $ 10,000,000      
Senior convertible notes due December 31, 2019          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Senior notes, effective interest rate   9.75%      
Principal amount of outstanding borrowings   $ 35,000,000      
Senior convertible notes due December 31, 2019 | Tranche B Notes          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Principal amount of outstanding borrowings   $ 45,000,000   $ 54,407,000  
Deerfield          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Principal amount of outstanding borrowings       39,400,000  
Deerfield | Tranche B Notes          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Principal amount of outstanding borrowings       $ 15,000,000  
Deerfield | Senior convertible notes due December 31, 2019          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Senior notes, effective interest rate   9.75%      
Deerfield | Senior convertible notes due December 31, 2019 | Tranche B Notes          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Senior notes, effective interest rate   8.75%      
Minimum | AFREZZA product sales          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Sales return right following product expiration in months   6 months      
Minimum | Deerfield | Senior convertible notes due December 31, 2019 | Tranche B Notes          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Available amount of credit facility under covenant restrictions   $ 25,000,000      
Maximum | AFREZZA product sales          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]          
Sales return right following product expiration in months   12 months